Journal
BLOOD CANCER JOURNAL
Volume 11, Issue 3, Pages -Publisher
SPRINGERNATURE
DOI: 10.1038/s41408-021-00457-9
Keywords
-
Categories
Ask authors/readers for more resources
EVI1 is an oncogenic zinc-finger transcription factor that is overexpressed in myeloid malignancies and correlates with poor clinical outcomes. Despite advancements in understanding the biology of EVI1 dysregulation, significant improvements in therapeutic outcomes remain elusive.
Ecotropic viral integration site 1 (Evi1) was discovered in 1988 as a common site of ecotropic viral integration resulting in myeloid malignancies in mice. EVI1 is an oncogenic zinc-finger transcription factor whose overexpression contributes to disease progression and an aggressive phenotype, correlating with poor clinical outcome in myeloid malignancies. Despite progress in understanding the biology of EVI1 dysregulation, significant improvements in therapeutic outcome remain elusive. Here, we highlight advances in understanding EVI1 biology and discuss how this new knowledge informs development of novel therapeutic interventions. EVI1 is overexpression is correlated with poor outcome in some epithelial cancers. However, the focus of this review is the genetic lesions, biology, and current therapeutics of myeloid malignancies overexpressing EVI1.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available